Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT)

K Gordon,A B Gottlieb,D Thaçi,Y Poulin,F Brock,R B Warren,A Blauvelt,K Reich,M Boehnlein,C Arendt

doi:10.25251/skin.4.supp.45

Abstract

Abstract not available.

Highlights

Certolizumab pegol (CZP), an Fc-free, PEGylated anti-tumor necrosis factor, has demonstrated efficacy and safety in moderate to severe plaque psoriasis (PSO).[1,2]
CZP: certolizumab pegol; DLQI 0/1: Dermatology Life Quality Index of 0 or 1; no effect of disease on quality of life; PASI 75: 75% improvement from baseline in Psoriasis Area Severity Index; Q2W: every two weeks

Summary

Introduction

Certolizumab pegol (CZP), an Fc-free, PEGylated anti-tumor necrosis factor (anti-TNF), has demonstrated efficacy and safety in moderate to severe plaque psoriasis (PSO).[1,2]. BSA: body surface area; CZP: certolizumab pegol; DLQI: Dermatology Life Quality Index; IL: interleukin; PASI: Psoriasis Area Severity Index; PGA: physician’s Global Assessment; PsA: psoriatic arthritis; PSO: plaque psoriasis; Q2W: every two weeks; SD: standard deviation; TNF: tumor necrosis factor.

Results

Conclusion